Improving Medication Use and Outcomes in Older Adults with Dementia after Hospitalization: Effectiveness of Medicare Programs
改善老年痴呆症患者住院后的药物使用和结果:医疗保险计划的有效性
基本信息
- 批准号:10593952
- 负责人:
- 金额:$ 15.52万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:Adverse drug eventAdverse effectsAdvisory CommitteesAffectAftercareAgingAlzheimer&aposs disease related dementiaAmericanAwardBehavioral ModelCaregiversCaringCentral Nervous System AgentsClinicalCognitionDataDeliriumDementiaDevelopment PlansDoctor of PharmacyDoctor of PhilosophyDrug InteractionsEducationEffectivenessElderlyEligibility DeterminationEmergency department visitEnsureEnvironmentEpidemiologyExposure toFemaleGoalsHealthHealth PolicyHealth ServicesHealthcareHospitalizationHospitalsImpaired cognitionIncomeInpatientsK-Series Research Career ProgramsLogistic RegressionsLow incomeManaged CareMeasuresMedicareMedicare Part BMentorsMentorshipMethodologyMethodsMichiganMissionNational Institute on AgingNeurocognitiveOutcomePatientsPersonsPharmaceutical PreparationsPharmacistsPharmacy facilityPhysiciansPoliciesPublic PolicyQuality of CareResearchResearch MethodologyResearch PersonnelResearch ProposalsResourcesRiskRisk FactorsScienceScientistTestingTrainingUniversitiesVisitWorkacute careadverse outcomebeneficiarycareer developmentcollegecomorbiditycosteffectiveness evaluationeffectiveness testinghealth service usehospital readmissionhospitalization ratesimprovedindexingmalememberpaymentpoor health outcomeprimary outcomeprofessorprogramspublic health relevanceracial minoritysecondary outcomestatistics
项目摘要
PROJECT SUMMARY/ABSTRACT
Hospitalizations and medication problems after discharge are a major risk factor for poor health outcomes in
older adults with Alzheimer's disease and related dementia (ADRD). Increased preventable medication
problems, such as unnecessary continuation of medications with neurocognitive adverse effects, emergency
department visits, readmissions, and costs after hospitalization are a significant burden for older adults with
ADRD. A better understanding of how patient and healthcare factors contribute to use of medications with
neurocognitive effects and poor outcomes after hospitalization will inform policies to improve medication-
related outcomes and care transitions in older adults with ADRD. This K08 Mentored Clinical Scientist
Research Career Development Award application (PA-20-203) is to support Antoinette B. Coe, PharmD, PhD,
a pharmacist-scientist and Assistant Professor in the University of Michigan College of Pharmacy. Dr. Coe's
long-term goal is to become an independent investigator advancing the science of medication use in aging with
a research program demonstrating ways to ensure safe and effective medication use in older adults, especially
those who are vulnerable, cognitively impaired, and have ADRD. To achieve this goal, Dr. Coe will carry out
the scientific aims of this proposal along with a robust career development plan in which she will acquire
content expertise in cognitive impairment, ADRD, and aging, gain advanced epidemiology statistics training
including causal inference methods, and develop an understanding of health and public policy impact on
ADRD outcomes. The overarching scientific goal of this mentored-research proposal is to understand how poor
outcomes related to medications with neurocognitive effects after a hospitalization can be mitigated in older
adults with ADRD. This proposal leverages two existing Medicare care programs and payment policies that
include medication reviews as potential solutions to reduce inappropriate neurocognitive medication use after
care transitions: Medicare Part D Comprehensive Medication Reviews (CMR) and Part B Transitional Care
Management (TCM) visits. Using nationally representative Medicare administrative data, the specific aims are
as follows: 1) Identify predictors of inappropriate neurocognitive medication use in older adults with ADRD after
hospitalization, 2) Examine the use of medication reviews (both CMR and TCM) among older adults who have
been hospitalized and assess factors associated with their use, and 3) Test the effectiveness of
comprehensive medication reviews and transitional care management on outcomes in older adults with ADRD
after hospitalization. Dr. Coe will conduct all work at the rich environment of the University of Michigan, with an
exceptional mentoring and advisory team led by Dr. Julie Bynum. The study's results will inform a large-scale
R01-level application testing strategies to increase medication reviews in older adults with ADRD and their
caregivers and motivate Medicare policy changes to ensure safe medication use in older adults with ADRD.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Antoinette Bartolotta Coe其他文献
Antoinette Bartolotta Coe的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Antoinette Bartolotta Coe', 18)}}的其他基金
Improving Medication Use and Outcomes in Older Adults with Dementia after Hospitalization: Effectiveness of Medicare Programs
改善老年痴呆症患者住院后的药物使用和结果:医疗保险计划的有效性
- 批准号:
10381580 - 财政年份:2021
- 资助金额:
$ 15.52万 - 项目类别:
Improving Medication Use and Outcomes in Older Adults with Dementia after Hospitalization: Effectiveness of Medicare Programs
改善老年痴呆症患者住院后的药物使用和结果:医疗保险计划的有效性
- 批准号:
10188737 - 财政年份:2021
- 资助金额:
$ 15.52万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 15.52万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 15.52万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 15.52万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 15.52万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 15.52万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 15.52万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 15.52万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 15.52万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 15.52万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 15.52万 - 项目类别:
Discovery Grants Program - Individual














{{item.name}}会员




